<DOC>
	<DOC>NCT02701985</DOC>
	<brief_summary>This is a randomized, double-blind, placebo-controlled, two-treatment arm, parallel-group study designed to evaluate the effects of RO5459072 treatment on disease activity and symptoms of Sjogren's syndrome in adult participants with moderate to severe primary Sjogren's syndrome.</brief_summary>
	<brief_title>A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Sjogren's Syndrome</mesh_term>
	<criteria>A diagnosis of primary Sjogren's syndrome according to the revised AmericanEuropean Consensus Group (AECG) criteria European League against Rheumatism (EULAR) Sjogren's Syndrome Disease Activity Index (ESSDAI) score &gt;=5 EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) score &gt;=5 Elevated serum titers of antiSjogren'ssyndromerelated antigen A (antiSSA) and/or antiSjogren'ssyndromerelated antigen B (antiSSB) antibodies Negative pregnancy test (women) Willing to comply with the study procedures and restrictions, including measures to prevent pregnancy and restrictions on sperm donation A diagnosis of secondary Sjogren's syndrome Severe complications of Sjogren's syndrome Systemic immunosuppressant therapy, cyclophosphamide, or Bcell depleting therapy within 6 months prior to the screening visit Corticosteroid therapy exceeding 7.5 mg prednisone equivalents per day A history suggesting reduced immune function or any other conditions predisposing patients to serious infection A history of lymphoma, myeloma or monoclonal gammopathy of unknown significance (MGUS), or any other malignancies within the past 5 years A diagnosis of fibromyalgia or significant depression Having any concomitant disease or condition that could interfere with the conduct of the study, or that would pose an unacceptable risk to the individual Participation in an investigational drug or device study within 3 months prior to screening Inability to comply with the study protocol for any other reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>